Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Single-dose and steady-state pharmacokinetics of ospemifene, a selective estrogen receptor modulator, in postmenopausal women.

Koskimies P, Turunen J, Lammintausta R, Scheinin M.

Int J Clin Pharmacol Ther. 2013 Nov;51(11):861-7. doi: 10.5414/CP201925.

PMID:
24075094
2.

Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.

Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group..

Menopause. 2013 Jun;20(6):623-30. doi: 10.1097/gme.0b013e318279ba64.

PMID:
23361170
3.

The effect of renal and hepatic impairment on the pharmacokinetics of ospemifene, a tissue-selective estrogen agonist/antagonist.

Preston RA, Marbury TC, Wajima T, Graham S.

Am J Ther. 2015 May-Jun;22(3):171-81. doi: 10.1097/01.mjt.0000434044.39502.64.

PMID:
24413373
4.

Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.

Simon J, Portman D, Mabey RG Jr; Ospemifene Study Group..

Maturitas. 2014 Mar;77(3):274-81. doi: 10.1016/j.maturitas.2013.12.005.

5.

Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women.

Cristina Castelli M, Bhaskar S, Lippman J.

Clin Ther. 2013 Jun;35(6):862-9. doi: 10.1016/j.clinthera.2013.05.001.

PMID:
23795577
6.

Ospemifene for the treatment of dyspareunia in postmenopausal women.

Paton DM.

Drugs Today (Barc). 2014 May;50(5):357-64. doi: 10.1358/dot.2014.50.5.2134451. Review.

PMID:
24918836
8.

One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.

Simon JA, Lin VH, Radovich C, Bachmann GA; Ospemifene Study Group..

Menopause. 2013 Apr;20(4):418-27. doi: 10.1097/gme.0b013e31826d36ba.

PMID:
23096251
9.

Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.

Wurz GT, Kao CJ, DeGregorio MW.

Clin Interv Aging. 2014 Nov 13;9:1939-50. doi: 10.2147/CIA.S73753. Review.

10.

Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.

DeGregorio MW, Zerbe RL, Wurz GT.

Steroids. 2014 Nov;90:82-93. doi: 10.1016/j.steroids.2014.07.012. Review.

PMID:
25087944
11.

Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.

Bachmann GA, Komi JO; Ospemifene Study Group..

Menopause. 2010 May-Jun;17(3):480-6. doi: 10.1097/gme.0b013e3181c1ac01.

PMID:
20032798
12.

Profile of ospemifene in the breast.

Berga SL.

Reprod Sci. 2013 Oct;20(10):1130-6. doi: 10.1177/1933719113497290. Review.

PMID:
23945733
13.

Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.

Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA.

Climacteric. 2015 Apr;18(2):226-32. doi: 10.3109/13697137.2014.954996.

14.

Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.

Lehtinen T, Tolonen A, Turpeinen M, Uusitalo J, Vuorinen J, Lammintausta R, Pelkonen O, Scheinin M.

Biopharm Drug Dispos. 2013 Oct;34(7):387-95. doi: 10.1002/bdd.1853.

PMID:
23852652
15.

Tissue selectivity of ospemifene: pharmacologic profile and clinical implications.

Kangas L, Unkila M.

Steroids. 2013 Dec 11;78(12-13):1273-80. doi: 10.1016/j.steroids.2013.09.003. Review.

PMID:
24055829
16.

Ospemifene: first global approval.

Elkinson S, Yang LP.

Drugs. 2013 May;73(6):605-12. doi: 10.1007/s40265-013-0046-y. Review.

PMID:
23605694
17.

Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause.

Unkila M, Kari S, Yatkin E, Lammintausta R.

J Steroid Biochem Mol Biol. 2013 Nov;138:107-15. doi: 10.1016/j.jsbmb.2013.04.004.

PMID:
23665515
18.

The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.

Cui Y, Zong H, Yan H, Li N, Zhang Y.

J Sex Med. 2014 Feb;11(2):487-97. doi: 10.1111/jsm.12377. Review.

PMID:
24251418
19.

Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women.

Komi J, Lankinen KS, Härkönen P, DeGregorio MW, Voipio S, Kivinen S, Tuimala R, Vihtamäki T, Vihko K, Ylikorkala O, Erkkola R.

Menopause. 2005 Mar;12(2):202-9.

PMID:
15772568
20.

Effects of ospemifene on breast tissue morphology and proliferation: a comparative study versus other selective estrogen receptor modulators in ovariectomized rats.

Kangas L, Härkönen P, Väänänen K, Keskitalo J, Eigéliené N.

Horm Metab Res. 2014 May;46(5):328-32. doi: 10.1055/s-0034-1367032.

PMID:
24526372

Supplemental Content

Support Center